{"entity":{"id":"nct06668961","kind":"trial","name":"A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Sq","aka":[],"tldr":"A phase 2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06668961 by Sichuan Baili Pharmaceutical Co., Ltd., with 48 participants enrolled, started 2024-11-07 and due to reach its primary completion in 2026-11. Interventions recorded: SI-B001, SI-B003. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06668961","url":"https://clinicaltrials.gov/study/NCT06668961"}],"tags":["ctgov-ingest"],"related":[],"cancers":["head-and-neck","recurrent-metastatic-hnscc"],"sections":[],"technologies":[],"targets":[],"drugs":["si-b001"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06668961","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Safety and Efficacy of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy (SI-B001+SI-B003+ Platinum-based Chemotherapy) as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT06668961","source":"https://clinicaltrials.gov/study/NCT06668961","fetchedAt":"2026-10-07T16:54:54.827Z","studySha256":"a0497b5ffacc46e090edd77d1ba5d509cf43b2b0bf891b2dd13a899876550d58","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-27","leadSponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":48,"enrolmentType":"ACTUAL","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-11-07","startedType":"actual","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06668961/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/"}],"drug":[{"id":"si-b001","kind":"drug","name":"SI-B001","route":"/drugs/si-b001/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}